Last reviewed · How we verify
Placebo Inhalation Powder Diskus
Placebo Inhalation Powder Diskus is a Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Clinical trial control comparator (indication unknown without active drug specification).
Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.
Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials. Used for Clinical trial control comparator (indication unknown without active drug specification).
At a glance
| Generic name | Placebo Inhalation Powder Diskus |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo inhalation powder serves as a comparator in phase 3 clinical trials to establish the efficacy and safety of an active investigational drug relative to no treatment effect. Any observed clinical benefit from placebo is attributable to the placebo effect—psychological and contextual factors rather than direct molecular action. This formulation allows for blinded assessment of the true therapeutic benefit of the active agent being studied.
Approved indications
- Clinical trial control comparator (indication unknown without active drug specification)
Common side effects
Key clinical trials
- A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100mcg/Blister Oral Inhalation Powder/GSK in Patients With Asthma (PHASE3)
- Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma (PHASE3)
- An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs. (PHASE2)
- Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma (PHASE3)
- A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation (PHASE2)
- An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease (PHASE2)
- BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients (PHASE3)
- Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Inhalation Powder Diskus CI brief — competitive landscape report
- Placebo Inhalation Powder Diskus updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI